RFG Advisory LLC Acquires Shares of 324,397 Altimmune, Inc. (NASDAQ:ALT)

RFG Advisory LLC purchased a new stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 324,397 shares of the company's stock, valued at approximately $1,622,000. RFG Advisory LLC owned approximately 0.42% of Altimmune as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Wells Fargo & Company MN raised its holdings in shares of Altimmune by 69.3% in the 4th quarter. Wells Fargo & Company MN now owns 215,538 shares of the company's stock valued at $1,554,000 after purchasing an additional 88,209 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Altimmune in the 4th quarter worth approximately $45,000. Marshall Wace LLP purchased a new position in shares of Altimmune in the 4th quarter worth approximately $472,000. Bellevue Group AG grew its position in shares of Altimmune by 9.5% in the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company's stock worth $6,817,000 after buying an additional 81,786 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Altimmune by 21.7% in the 4th quarter. Bank of America Corp DE now owns 181,889 shares of the company's stock worth $1,311,000 after buying an additional 32,382 shares during the last quarter. Institutional investors own 78.05% of the company's stock.

Altimmune Price Performance

NASDAQ:ALT traded up $0.16 during trading hours on Friday, hitting $5.62. 3,862,960 shares of the company were exchanged, compared to its average volume of 2,831,228. The stock has a market capitalization of $455.82 million, a price-to-earnings ratio of -3.63 and a beta of 0.58. Altimmune, Inc. has a 52-week low of $3.55 and a 52-week high of $11.16. The company's 50 day moving average price is $5.10 and its 200-day moving average price is $6.33.

Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.09. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the previous year, the firm earned ($0.34) EPS. On average, equities analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Insiders Place Their Bets

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was acquired at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ALT shares. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a research report on Thursday, April 3rd. William Blair reaffirmed a "market perform" rating on shares of Altimmune in a research report on Friday, March 14th. Finally, Wall Street Zen raised shares of Altimmune from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Altimmune has a consensus rating of "Moderate Buy" and an average price target of $20.20.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.